Xianbo Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xianbo Wu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Jie Wang
Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
4 shared publications- Jianyou Shi
Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
3 shared publications Quan Luo
West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People’s Hospital, Chengdu Second People’s Hospital
3 shared publicationsJianli Huang
Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
2 shared publicationsXinwei Yang
School of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan, China
2 shared publicationsYihua Xu
School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
2 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1871406
Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease
Psoriasis and Crohn’s disease are chronic immune-mediated inflammatory diseases affecting distinct barrier organs, yet epidemiological, genetic, transcriptomic, and therapeutic evidence supports partial immune convergence between them. This review argues that the relationship between psoriasis and Crohn’s disease reflects partial immune convergence shaped by tissue context, rather than a single shared disease entity. TNF-α and IL-23-centered type 17 immunity represent the most clinically relevant shared upstream programs, whereas downstream effector pathways, especially IL-17-related responses, are shaped differently by skin and gut barrier architecture, resident immune ecology, microbial exposure, and repair demands. We discuss the gut–skin axis with caution: barrier dysfunction, dysbiosis, microbial metabolites, and immune-cell trafficking may connect skin and intestinal inflammation, but direct causal evidence in humans remains limited. TNF inhibitors, IL-12/23 blockade, and selective IL-23 inhibitors are the most plausible options for selected patients requiring treatment compatible with both skin and gut disease, whereas IL-17 blockade and paradoxical psoriasiform reactions illustrate organ-specific therapeutic tensions. Future progress will depend on patient stratification using clinical phenotypes, biomarkers, tissue profiling, and treatment history to identify patients in whom skin and intestinal inflammation are driven by overlapping immune mechanisms.
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1871406
Open AccessShared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease
Psoriasis and Crohn’s disease are chronic immune-mediated inflammatory diseases affecting distinct barrier organs, yet epidemiological, genetic, transcriptomic, and therapeutic evidence supports partial immune convergence between them. This review argues that the relationship between psoriasis and Crohn’s disease reflects partial immune convergence shaped by tissue context, rather than a single shared disease entity. TNF-α and IL-23-centered type 17 immunity represent the most clinically relevant shared upstream programs, whereas downstream effector pathways, especially IL-17-related responses, are shaped differently by skin and gut barrier architecture, resident immune ecology, microbial exposure, and repair demands. We discuss the gut–skin axis with caution: barrier dysfunction, dysbiosis, microbial metabolites, and immune-cell trafficking may connect skin and intestinal inflammation, but direct causal evidence in humans remains limited. TNF inhibitors, IL-12/23 blockade, and selective IL-23 inhibitors are the most plausible options for selected patients requiring treatment compatible with both skin and gut disease, whereas IL-17 blockade and paradoxical psoriasiform reactions illustrate organ-specific therapeutic tensions. Future progress will depend on patient stratification using clinical phenotypes, biomarkers, tissue profiling, and treatment history to identify patients in whom skin and intestinal inflammation are driven by overlapping immune mechanisms.
- Open Access
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1745024
The mechanism of the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma: current developments and future prospects
Renal cell carcinoma (RCC) is a type of solid tumor with one of the highest incidences among urinary system malignancies, and its incidence continues to increase worldwide. The PI3K-AKT-mTOR signaling pathway, as a central signaling hub that regulates biological processes such as cell survival, proliferation, metabolism, and metastasis, often exhibits abnormal and sustained activation during the pathological progression of RCC. Dysregulation of this pathway synergistically promotes tumor progression through multiple mechanisms, including enhancing the survival and clonal expansion of tumor cells, inducing angiogenesis, driving metabolic reprogramming of the tumor microenvironment, and mediating treatment resistance. These pathological changes are closely associated with poor patient prognosis. Given the central role of the PI3K-AKT-mTOR signaling pathway in the pathogenesis of RCC, it has become a key target for targeted therapeutic intervention. Although multiple small-molecule inhibitors targeting this pathway have demonstrated potential for inhibiting tumor growth in preclinical studies and early-phase clinical trials, their clinical application still faces numerous challenges. Against this backdrop, combination therapy strategies offer a new approach to overcome the limitations of single-agent therapy, not only enhancing treatment efficacy but also potentially reducing the risk of drug resistance. Notably, natural products and their derivatives, due to their low toxicity, ability to modulate multiple targets, and specific inhibitory effects on cancer stem cells, are regarded as promising sensitizers in combination therapy. This article systematically reviews the pathological features of RCC and current clinical treatment strategies, with a focus on exploring the molecular regulatory mechanisms of the PI3K-AKT-mTOR signaling pathway in tumor progression, while highlighting the latest research advances in small-molecule inhibitors targeting this pathway. Integrating preclinical mechanistic studies and relevant clinical trial data, the limitations of existing agents are analyzed, and potential optimization directions are proposed, aiming to provide theoretical support and practical references for the clinical translation of precision therapy for RCC and to promote the transformation of pathway-based combination therapy models into clinical applications.
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1745024
Open AccessThe mechanism of the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma: current developments and future prospects
Renal cell carcinoma (RCC) is a type of solid tumor with one of the highest incidences among urinary system malignancies, and its incidence continues to increase worldwide. The PI3K-AKT-mTOR signaling pathway, as a central signaling hub that regulates biological processes such as cell survival, proliferation, metabolism, and metastasis, often exhibits abnormal and sustained activation during the pathological progression of RCC. Dysregulation of this pathway synergistically promotes tumor progression through multiple mechanisms, including enhancing the survival and clonal expansion of tumor cells, inducing angiogenesis, driving metabolic reprogramming of the tumor microenvironment, and mediating treatment resistance. These pathological changes are closely associated with poor patient prognosis. Given the central role of the PI3K-AKT-mTOR signaling pathway in the pathogenesis of RCC, it has become a key target for targeted therapeutic intervention. Although multiple small-molecule inhibitors targeting this pathway have demonstrated potential for inhibiting tumor growth in preclinical studies and early-phase clinical trials, their clinical application still faces numerous challenges. Against this backdrop, combination therapy strategies offer a new approach to overcome the limitations of single-agent therapy, not only enhancing treatment efficacy but also potentially reducing the risk of drug resistance. Notably, natural products and their derivatives, due to their low toxicity, ability to modulate multiple targets, and specific inhibitory effects on cancer stem cells, are regarded as promising sensitizers in combination therapy. This article systematically reviews the pathological features of RCC and current clinical treatment strategies, with a focus on exploring the molecular regulatory mechanisms of the PI3K-AKT-mTOR signaling pathway in tumor progression, while highlighting the latest research advances in small-molecule inhibitors targeting this pathway. Integrating preclinical mechanistic studies and relevant clinical trial data, the limitations of existing agents are analyzed, and potential optimization directions are proposed, aiming to provide theoretical support and practical references for the clinical translation of precision therapy for RCC and to promote the transformation of pathway-based combination therapy models into clinical applications.
- 30 October 2025
- Published by Elsevier in International Journal of Orthopaedic and Trauma Nursing
- Vol. 59, 101238
Nurse-led intervention in deep vein thrombosis development following major orthopedic surgery: A quality improvement project
- 30 October 2025
- Published by Elsevier in International Journal of Orthopaedic and Trauma Nursing
- Vol. 59, 101238
Nurse-led intervention in deep vein thrombosis development following major orthopedic surgery: A quality improvement project
- 24 November 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 321, 117485
Jiawei guomin decoction regulates the degranulation of mast cells in atopic dermatitis mice via the HIS/PAR-2 pathway
- 24 November 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 321, 117485
Jiawei guomin decoction regulates the degranulation of mast cells in atopic dermatitis mice via the HIS/PAR-2 pathway
- 12 June 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 121, 110434
Recent progress on tyrosine kinase 2 JH2 inhibitors
- 12 June 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 121, 110434
Recent progress on tyrosine kinase 2 JH2 inhibitors
- Open Access
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1029949
Efficacy and safety of Chinese herbal medicine in the treatment of chronic pruritus: A systematic review and meta-analysis of randomized controlled trials
Background: Chronic pruritus (CP) is a common and aggravating symptom associated with skin and systemic diseases. Although clinical reports suggest that Chinese herbal medicine (CHM) is safe and effective in Chronic pruritus treatment, evidence to prove it is lacking. Therefore, in this review, we evaluated the therapeutic effects and safety of Chinese herbal medicine for the treatment of Chronic pruritus.Methods: Nine databases were searched for relevant randomized controlled trials (RCTs) from the inception of the database to 20 April 2022. The randomized controlled trials that compared the treatment of Chinese herbal medicine or a combination of Chinese herbal medicine and conventional western medicine treatment (WM) with western medicine treatment intervention for patients with Chronic pruritus were selected. We evaluated the effects of treatment with Chinese herbal medicine on the degree of pruritus, the Dermatology Life Quality Index (DLQI) score, response rate, recurrence rate, and incidence of adverse events in patients with Chronic pruritus. The risk of bias in each trial was evaluated using the Cochrane Collaboration tool. The RevMan software (version 5.3) was used for performing meta-analyses to determine the comparative effects.Results: Twenty-four randomized controlled trials were included, compared with placebo, moderate-quality evidence from one study showed that Chinese herbal medicine was associated with reduced visual analogue scale (VAS) (MD: −2.08; 95% CI = −2.34 to −1.82). Compared with western medicine treatment, low-to moderate-quality evidence from 8 studies indicated that Chinese herbal medicine was associated with reduced visual analogue scale, 4 studies indicated that Chinese herbal medicine was associated with reduced Dermatology Life Quality Index (MD = −1.80, 95% CI = −2.98 to −.62), and 7 studies indicated that Chinese herbal medicine was associated with improved Effective rate (RR: 1.26; 95% CI = 1.19–1.34). Compared with combination of Chinese herbal medicine and western medicine treatment, 16 studies indicated that Chinese herbal medicine was associated with reduced visual analogue scale, 4 studies indicated that Chinese herbal medicine was associated with reduced Dermatology Life Quality Index (MD = −2.37, 95% CI = −2.61 to −2.13), and 13 studies indicated that Chinese herbal medicine was associated with improved Effective rate (RR: 1.28; 95% CI = 1.21–1.36). No significant difference in the occurrence of adverse events in using Chinese herbal medicine or western medicine treatment was reported.Conclusion: The efficacy of Chinese herbal medicine used with or without western medicine treatment was better than western medicine treatment in treating chronic pruritus. However, only a few good studies are available regarding Chronic pruritus, and thus, high-quality studies are necessary to validate the conclusions of this study.
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1029949
Open AccessEfficacy and safety of Chinese herbal medicine in the treatment of chronic pruritus: A systematic review and meta-analysis of randomized controlled trials
Background: Chronic pruritus (CP) is a common and aggravating symptom associated with skin and systemic diseases. Although clinical reports suggest that Chinese herbal medicine (CHM) is safe and effective in Chronic pruritus treatment, evidence to prove it is lacking. Therefore, in this review, we evaluated the therapeutic effects and safety of Chinese herbal medicine for the treatment of Chronic pruritus.Methods: Nine databases were searched for relevant randomized controlled trials (RCTs) from the inception of the database to 20 April 2022. The randomized controlled trials that compared the treatment of Chinese herbal medicine or a combination of Chinese herbal medicine and conventional western medicine treatment (WM) with western medicine treatment intervention for patients with Chronic pruritus were selected. We evaluated the effects of treatment with Chinese herbal medicine on the degree of pruritus, the Dermatology Life Quality Index (DLQI) score, response rate, recurrence rate, and incidence of adverse events in patients with Chronic pruritus. The risk of bias in each trial was evaluated using the Cochrane Collaboration tool. The RevMan software (version 5.3) was used for performing meta-analyses to determine the comparative effects.Results: Twenty-four randomized controlled trials were included, compared with placebo, moderate-quality evidence from one study showed that Chinese herbal medicine was associated with reduced visual analogue scale (VAS) (MD: −2.08; 95% CI = −2.34 to −1.82). Compared with western medicine treatment, low-to moderate-quality evidence from 8 studies indicated that Chinese herbal medicine was associated with reduced visual analogue scale, 4 studies indicated that Chinese herbal medicine was associated with reduced Dermatology Life Quality Index (MD = −1.80, 95% CI = −2.98 to −.62), and 7 studies indicated that Chinese herbal medicine was associated with improved Effective rate (RR: 1.26; 95% CI = 1.19–1.34). Compared with combination of Chinese herbal medicine and western medicine treatment, 16 studies indicated that Chinese herbal medicine was associated with reduced visual analogue scale, 4 studies indicated that Chinese herbal medicine was associated with reduced Dermatology Life Quality Index (MD = −2.37, 95% CI = −2.61 to −2.13), and 13 studies indicated that Chinese herbal medicine was associated with improved Effective rate (RR: 1.28; 95% CI = 1.21–1.36). No significant difference in the occurrence of adverse events in using Chinese herbal medicine or western medicine treatment was reported.Conclusion: The efficacy of Chinese herbal medicine used with or without western medicine treatment was better than western medicine treatment in treating chronic pruritus. However, only a few good studies are available regarding Chronic pruritus, and thus, high-quality studies are necessary to validate the conclusions of this study.